Our knowledge of epigenetics and molecular genetics of rare tumors has increased very rapidly in the last few years. Innovative data on epigenetics and molecular genetics of rare tumors identified new mechanisms of transformation and novel targets for an early diagnosis and innovative treatments. Indeed, the art of the study of this topic has provided new clinical applications for those rare tumors, which have previously been considered incurable. Epigenetics and molecular genetics features, and the mechanisms of the onset of rare tumors, are of paramount importance to understand and verify new target genes/their products for innovative therapeutic approaches in clinical oncology.
This collection is dedicated to the epigenetics and molecular genetics of rare human tumors. The goal of this collection is to provide an overview of recent advanced investigations dedicated to the mechanisms of the onset of rare tumors, specifically focused on the epigenetic changes that may occur during the oncogenesis, such as gene methylation/demethylation, chromatin remodeling/histone modifications including acetylation/deacetylation, and microRNA dysregulation.
Indeed, demethylating agents, monoclonal antibodies, experimental compounds, immune therapies, stem cells, altogether may represent a kaleidoscopic new tool to contrast rare tumors, which are currently considered to be incurable/fatal cancers. Epigenetic and molecular genetic investigations are very significant to reveal the signature of rare tumors, thus allowing in a short period of time the translation of the new achievements from the laboratory to the clinical applications. This Research Topic is aimed at readers interested in the epigenetics and molecular genetics of rare tumors and clinical applications, with specific attention given to new genetic assays and personalized/precise medicine approaches. Overall, patients affected by rare tumors may benefit of these innovative investigations and the translational medicine derived from them.
Contributors are encouraged to submit their articles and reviews on this topic with specific attention to microRNA, gene promoter methylation, chromatin/histone remodeling, gene expression modification fields.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
Our knowledge of epigenetics and molecular genetics of rare tumors has increased very rapidly in the last few years. Innovative data on epigenetics and molecular genetics of rare tumors identified new mechanisms of transformation and novel targets for an early diagnosis and innovative treatments. Indeed, the art of the study of this topic has provided new clinical applications for those rare tumors, which have previously been considered incurable. Epigenetics and molecular genetics features, and the mechanisms of the onset of rare tumors, are of paramount importance to understand and verify new target genes/their products for innovative therapeutic approaches in clinical oncology.
This collection is dedicated to the epigenetics and molecular genetics of rare human tumors. The goal of this collection is to provide an overview of recent advanced investigations dedicated to the mechanisms of the onset of rare tumors, specifically focused on the epigenetic changes that may occur during the oncogenesis, such as gene methylation/demethylation, chromatin remodeling/histone modifications including acetylation/deacetylation, and microRNA dysregulation.
Indeed, demethylating agents, monoclonal antibodies, experimental compounds, immune therapies, stem cells, altogether may represent a kaleidoscopic new tool to contrast rare tumors, which are currently considered to be incurable/fatal cancers. Epigenetic and molecular genetic investigations are very significant to reveal the signature of rare tumors, thus allowing in a short period of time the translation of the new achievements from the laboratory to the clinical applications. This Research Topic is aimed at readers interested in the epigenetics and molecular genetics of rare tumors and clinical applications, with specific attention given to new genetic assays and personalized/precise medicine approaches. Overall, patients affected by rare tumors may benefit of these innovative investigations and the translational medicine derived from them.
Contributors are encouraged to submit their articles and reviews on this topic with specific attention to microRNA, gene promoter methylation, chromatin/histone remodeling, gene expression modification fields.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
